Related Experiment Video

Updated: Jan 23, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

18.6K

Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the

Stefanie Schüpke1,2, Ralph Hein-Rothweiler3, Katharina Mayer1

  • 1Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen, Technische Universität, Munich, Germany.

Thrombosis and Haemostasis
|June 22, 2019
PubMed

Insights

Revacept, a novel antiplatelet therapy, aims to reduce ischemic events after percutaneous coronary intervention (PCI) without increasing bleeding risk. This study evaluates its efficacy and safety in patients undergoing PCI.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Patients undergoing percutaneous coronary intervention (PCI) on dual antiplatelet therapy still face periprocedural ischemic events.
  • Current antithrombotic drugs increase bleeding risk, highlighting an unmet need for safer, more effective treatments.

Purpose of the Study:

  • To assess the efficacy and safety of Revacept, a novel lesion-directed antithrombotic agent, in patients undergoing elective PCI.
  • To evaluate Revacept's ability to inhibit collagen-mediated platelet aggregation at the site of vascular injury.

Main Methods:

  • A randomized, double-blind, placebo-controlled Phase II trial (ISAR-PLASTER) involving 332 patients with stable coronary artery disease undergoing elective PCI.
  • Patients received either Revacept (160 mg or 80 mg) or placebo intravenously before PCI, alongside standard dual antiplatelet therapy and anticoagulation.
  • Primary endpoint: composite of death or myocardial injury within 48 hours. Safety endpoint: Bleeding Academic Research Consortium class 2 or higher bleeding at 30 days.

Main Results:

  • The study is designed to assess the primary composite endpoint of death or myocardial injury.
  • The safety endpoint will evaluate the incidence of significant bleeding events (BARC class ≥2) within 30 days post-intervention.
  • This trial represents the first assessment of Revacept's efficacy and safety in patients undergoing elective PCI.

Conclusions:

  • Revacept is a novel, lesion-directed antithrombotic targeting collagen-mediated platelet adhesion.
  • The ISAR-PLASTER trial will provide crucial data on the efficacy and safety profile of Revacept in the context of PCI.
  • Findings may lead to improved antithrombotic strategies for patients undergoing PCI, addressing the dual challenge of ischemic events and bleeding risk.

More Related Videos

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture05:33

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture

Published on: August 4, 2023

2.2K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.8K

Related Concept Videos

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
242
Group Design02:01

Group Design

The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
10.3K
Adhesion01:14

Adhesion

Adhesion occurs when one type of molecule is attracted to a different molecule. Water exhibits adhesive properties in the presence of polar surfaces, such as glass or cellulose in plants. For instance, when water is poured into a glass, the positively charged hydrogen molecules of water are more attracted to the negatively charged oxygen molecules in the silica than to the oxygen in neighboring water molecules.
Capillary action is a result of water’s adhesive tendencies. When a narrow...
43.7K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
146
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K